Avenue Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-2.91	-11.65	-10.38	-3.55	-3.73	Upgrade
Asset Writedown & Restructuring Costs	-	-	3	-	-	Upgrade
Stock-Based Compensation	0.67	1.24	0.91	0.65	0.44	Upgrade
Other Operating Activities	0.11	1.21	-2.69	-5.1	-	Upgrade
Change in Accounts Receivable	-	-	-	0.09	-0.09	Upgrade
Change in Accounts Payable	0.3	0.19	-0.36	0.35	-0.38	Upgrade
Change in Other Net Operating Assets	0	-0.01	0.07	-0.03	0.01	Upgrade
Operating Cash Flow	-1.83	-9.03	-9.45	-7.6	-3.75	Upgrade
Sale (Purchase) of Intangibles	-	-	-3	-	-	Upgrade
Investing Cash Flow	-	-	-3	-	-	Upgrade
Issuance of Common Stock	2.09	11.04	7.53	11.65	5.04	Upgrade
Repurchase of Common Stock	-	-	-	-1.1	-	Upgrade
Other Financing Activities	-	-1.21	-	-	-0.66	Upgrade
Financing Cash Flow	2.09	9.84	7.53	10.54	4.38	Upgrade
Net Cash Flow	0.26	0.81	-4.93	2.95	0.63	Upgrade
Levered Free Cash Flow	-1.1	-6.21	-13.49	-1.25	-2.36	Upgrade
Unlevered Free Cash Flow	-1.1	-6.21	-13.49	-1.25	-2.36	Upgrade
Change in Working Capital	0.3	0.18	-0.29	0.41	-0.46	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.